This paper features the synthesis of thrombin-responsive, nucleic acid-gated, UiO-68 metal–
organic framework nanoparticles (NMOFs) loaded with the drug Apixaban or rhodamine 6G …

Importance of the field. New oral anticoagulants with favorable safety profiles and fixed
doses are required for the management of thromboembolism and stroke prevention in …

Introduction: The emergence of the direct oral anticoagulants (DOACs) offers patients more
convenient and accessible alternatives to warfarin or parenteral agents for the treatment of …

Demographic projections for hip fragility fractures indicate a rising annual incidence by
virtue of a multimorbid, ageing population with more noncommunicable diseases (NCDs) …

Apixaban is an oral, direct, and highly selective factor Xa inhibitor in late-stage clinical
development for the prevention and treatment of thromboembolic diseases. Apixaban was …

A sensitive and selective UPLC-MS/MS method was developed for the synchronized
determination of four drugs used in severe acute respiratory syndrome coronavirus 2 (SARS …

A 54-year-old Japanese man was diagnosed with blue rubber bleb nevus syndrome
(BRBNS) due to venodilation in the lower extremities at birth and gastrointestinal vascular …

Introduction Tissue factor-induced platelet aggregation and factor Xa (FXa) activity bound to
clot contribute to the formation and growth of thrombus. The effects of edoxaban, a direct …

The direct factor Xa inhibitor apixaban (Eliquis®) has predictable pharmacodynamics and
pharmacokinetics and does not require routine anticoagulation monitoring. This article …

Apixaban (Eliquis™) is an orally active and selective direct inhibitor of factor Xa indicated for
twice-daily use in the EU for the prevention of venous thromboembolism (VTE) in adults who …